SAB Biotherapeutics, Inc.

Big Cypress Acquisition Corp (Nasdaq: BCYP), sponsored by Big Cypress Holdings LLC, completed its initial public offering in 2020 targeting the healthcare and life sciences sector. The blank-check company filed a 10-Q with the SEC on May 21, 2021, covering routine quarterly disclosures during its target-search period. Big Cypress subsequently announced a business combination with SAB Biotherapeutics, a clinical-stage biopharmaceutical company developing human polyclonal antibodies using genetically engineered cattle, with the de-SPAC transaction closing in December 2021. The combined entity adopted a new trading identity following the merger completion. Visit SpacDesk and sign up for full filing history, deal timelines, and analytics on BCYP and hundreds of other SPAC transactions.